Quidel Corporation (QDEL) is Upgraded by Raymond James to Outperform

Quidel Corporation (QDEL) was Upgraded by Raymond James to ” Outperform”. Earlier the firm had a rating of “Mkt Perform ” on the company shares. Raymond James advised their investors in a research report released on Jun 13, 2016.

On the company’s financial health, Quidel Corporation reported $0.02 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Apr 27, 2016. Analyst had a consensus of $0.05. The company had revenue of $50.30 million for the quarter, compared to analysts expectations of $50.61 million. The company’s revenue was down -18.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.30 EPS.

Quidel Corporation closed down -0.54 points or -3.10% at $16.89 with 64,698 shares getting traded on Friday. Post opening the session at $17.26, the shares hit an intraday low of $15.79 and an intraday high of $17.26 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Feb 23, 2016, Douglas C Bryant (CEO) purchased 3,700 shares at $13.91 per share price. According to the SEC, on Dec 3, 2015, John Tamerius (SVP, Strat & Ext Affairs) sold 21,109 shares at $21.83 per share price.

Quidel Corporation is engaged in the development manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases women’s health and gastrointestinal diseases. The Company sells its products directly to end users and distributors in each case for professional use in physician offices hospitals clinical laboratories reference laboratories universities retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions including infectious diseases women’s health autoimmune diseases bone health thyroid diseases and fecal occult blood.

Quidel Corporation

Leave a Reply

Quidel Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Quidel Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.